Apricus Biosciences (APRI) Releases Earnings Results, Beats Estimates By $0.02 EPS

Share on StockTwits

Apricus Biosciences (NASDAQ:APRI) issued its earnings results on Wednesday. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, MarketWatch Earnings reports.

Shares of NASDAQ APRI traded up $0.02 during trading hours on Thursday, reaching $0.36. The stock had a trading volume of 3,296 shares, compared to its average volume of 1,309,529. The firm has a market capitalization of $8.20 million, a price-to-earnings ratio of -0.36 and a beta of 1.22. Apricus Biosciences has a twelve month low of $0.25 and a twelve month high of $3.34.

About Apricus Biosciences

Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.

Featured Article: Do You Need a Fiduciary?

Earnings History for Apricus Biosciences (NASDAQ:APRI)

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply